뇌손상 환자의 야간뇨에 대한 경구 데스모프레신의 효과 및 안전성 = Effect and Safety of Oral Desmopressin for Nocturia in Brain Injured Patients

다국어 초록 (Multilingual Abstract)

Objective: To assess the effect of oral desmopressin administration for nocturia and sleeping in brain injured patients and to confirm its safety.Method: 20 brain injured patients waking up more than twice a night for urination during sleeping have been subjected to take 0.1 mg of desmopressin at 9 p.m. everyday for 30 days. To analyze the effect of the drug before and after its administration, the frequency of patient's awakening for urination, duration of time to first urination after sleeping, total urination volume during sleeping and Pittsburgh sleep quality index (PSQI) were evaluated. All newly found symptoms one month after taking the medication were recorded to confirm the safety of the drug.
Results: After taking the medication, the mean urination frequency of 20 patients was reduced from 2.4 to 1.4, the mean duration of time to the first urination after sleeping was increased from 3.4 hours to 4.9 hours (p＜0.01). The mean PSQI score of 20 patients was decreased from 9.7 to 4.8 (p＜0.01). 2 patients had side effects (hyponatremia, headache).Conclusion: The oral administration of desmopressin was relatively safe and effective on brain injured patients with nocturia.

다국어 초록 (Multilingual Abstract)

Objective: To assess the effect of oral desmopressin administration for nocturia and sleeping in brain injured patients and to confirm its safety.Method: 20 brain injured patients waking up more than twice a night for urination during sleeping have been subjected to take 0.1 mg of desmopressin at 9 p.m. everyday for 30 days. To analyze the effect of the drug before and after its administration, the frequency of patient's awakening for urination, duration of time to first urination after sleeping, total urination volume during sleeping and Pittsburgh sleep quality index (PSQI) were evaluated. All newly found symptoms one month after taking the medication were recorded to confirm the safety of the drug.
Results: After taking the medication, the mean urination frequency of 20 patients was reduced from 2.4 to 1.4, the mean duration of time to the first urination after sleeping was increased from 3.4 hours to 4.9 hours (p＜0.01). The mean PSQI score of 20 patients was decreased from 9.7 to 4.8 (p＜0.01). 2 patients had side effects (hyponatremia, headache).Conclusion: The oral administration of desmopressin was relatively safe and effective on brain injured patients with nocturia.

참고문헌 (Reference)

1 Marinkovic S., "Voiding and sexual dysfunction after cerebrovascular accidents" 165 : 359-370, 2001

2 Aloba O. O., "Validity of the Pittsburgh Sleep Quality Index among Nigerian university students" 8 : 266-270, 2007

3 Gill J. C., "Treatment of urgent bleeding in von Willebrand disease" 120 : 21-25, 2007

4 Cho Y. W., "Sleep disorders in maintenance dialysis patients with end-stage renal disease" 21 : 492-497, 2003

5 Kelleher H. B., "Severe hyponatremia due to desmopressin" 30 : 45-47, 2006

6 Bang K. M., "Quality of sleep and health-related quality of life in patients with major mental disorders" 11 : 138-149, 2000

7 Carpenter J. S., "Psychometric evaluation of the Pittsburgh Sleep Quality Index" 45 : 5-13, 1998

8 Brittain K. R., "Prevalence and impact of urinary symptoms among community- dwelling stroke survivors" 31 : 886-891, 2000

9 Johnson T. M., "Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study" 7 : 6-11, 2006

10 Gribel G., "Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders" 11 : 1549-1559, 2005

11 Sakakibara R., "Nocturnal polyuria with abnormal circadian rhythm of plasma arginine vasopressin in post-stroke patients" 44 : 281-284, 2005

12 Asplund R., "Nocturia, nocturnal polyuria, and sleep quality in the eldery" 56 : 517-525, 2004

13 Spinazze S., "Metabolic emergencies" 58 : 79-89, 2006

14 Oh B. M., "Lower urinary tract symptoms in chronic stroke survivors: frequency and impact on quality of life" 29 : 450-456, 2005

15 Lose G., "Kerrebroeck PV. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women" 189 : 1106-1113, 2003

16 Shindel A., "Hyponatremia associated with desmopressin for the treatment of nocturnal polyuria" 60 : 344-, 2002

17 Kasper D. L., "Harrison's principles of internal medicine, 16th ed" McGraw-Hill 2102-, 2004

18 Kuo H. C., "Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years" 59 : 485-489, 2002

19 Naghizadeh S., "Effectiveness of oral desmopressin therapy in posterior urethral valve patients with polyuria and detection of factors affecting the therapy" 48 : 819-825, 2005

20 Abelson J. L., "Dose response of arginine vasopressin to the CCK-B agonist pentagastrin" 24 : 161-169, 2001

21 van Kerrebroeck P., "Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study" 52 : 221-229, 2007

22 Giekoop J. G., "Depression with above-normal plasma vasopressin: validation by relations with family history of depression and mixed anxiety and retardation" 141 : 201-211, 2006

23 Hirayama A., "Decrease in nocturnal urinary levels of arginine vasopressin in patients with nocturnal polyuria" 68 : 19-23, 2006

24 Robinson D., "Antidiuresis: a new concept in managing female daytime urinary incontinence" 93 : 996-1000, 2004

25 Kim H. A., "An evaluation of apnea-hypopnea index, sleep questionnaires, oropharyngeal findings and cephalometric parameters in patients with snoring" 23 : 215-221, 2005